Author | Year | Country | N | nc | np | RCT | N (men) | BMI | Preparation | Exercise | Age (mean) | Dose | Outcome |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Drobnic F | 2014 | Spain | 19 | 9 | 10 | Parallel | 19 | 24.6 | Meriva | Downhill running | 35.4 | 1 g bid | VAS CK |
Nicol LM | 2015 | New Zealand | 17 | 17 | 17 | Crossover | 17 | - | Capsules | Leg press | 33.8 | 2.5 gm bid | VAS CK TNF IL |
Tanabe Y | 2015 | japan | 14 | 14 | 14 | Crossover | 14 | 22 | Theracurmin | Elbow flexor | 23.5 | 150 mg bid | VAS CK TNF IL ROM |
McFarlin BK | 2016 | USA | 28 | 14 | 14 | Parallel | 10 | 22.5 | Longvida | Leg press | 19.5 | 200, 400, 1000 mg | VAS CK TNF IL |
Naknhostin-Roohi B | 2016 | Iran | 10 | 10 | 10 | Crossover | 10 | 25.6 | Theracurmin | squat exercises | 25 | 150 mg | VAS CK |
Basham SA | 2019 | USA | 20 | 20 | 20 | Crossover | 20 | 26.7 | CurcuFresh | Leg press | 21.7 | 1.5 g | VAS CK TNF |
Amalraj A | 2020 | India | 30 | 15 | 15 | Parallel | 12 | 23.3 | AB | Downhill running | 36 | 500 mg | VAS CK |
Jäger R | 2019 | USA | 63 | 42 | 21 | Parallel | 31 | 25.6 | CurcuWIN | Downhill running | 21 | 50, 200 mg | VAS |
Tanabe Y | 2019 | japan | 24 | 16 | 8 | Parallel | 24 | 22.1 | Theracurmin | Elbow flexor | 28.3 | 180 mg 7 day | VAS CK ROM |
Tanabe Y scan | 2019 | japan | 20 | 10 | 10 | Parallel | 20 | 23.5 | Theracurmin | Elbow flexors | 28.75 | 180 mg | VAS CK TNF IL ROM |
Cardaci TD | 2020 | USA | 23 | 11 | 12 | Parallel | 11 | 24.6 | UPS | Treadmill | 21.13 | 2 g | VAS |
Mallard AR | 2020 | New Zealand | 27 | 13 | 14 | Parallel | 27 | 25.6 | LipiSperse | LL resistance | 26 | 427 mg | VAS CK TNF IL |
Hillman AR | 2021 | USA | 22 | 11 | 11 | Parallel | 17 | 25.4 | Capsules | Plyometric | 21.5 | 475 mg | VAS CK |